WELLNESS
08/25/2016 12:53 pm ET Updated Aug 25, 2016

Sarah Jessica Parker Ends Mylan Partnership Over EpiPen Price Hike

"I'm left disappointed, saddened and deeply concerned by Mylan's actions."
Richard Shotwell/AP

Sarah Jessica Parker has ended her relationship with the controversial pharmaceutical company Mylan

In May, the actress joined forces with the makers of the EpiPen through a campaign called Anaphylaxis for Reel. At the time, Parker urged awareness for life-threatening allergies and revealed that the issue is personal for her because her 13-year-old son, James Wilkie Broderick, has a severe peanut and hazelnut allergy. 

But following reports that the company raised the price of their standard two-pack of EpiPens from $100 in 2009 to $600 in 2016, Parker publicly cut ties and condemned the price hike.

“I’m left disappointed, saddened and deeply concerned by Mylan’s actions,” she said in her statement on Instagram.

Her original ad from May: 

Parker and her son, James Wilkie:

Sarah Jessica Parker and her son, James Wilkie Broderick.
Walter McBride via Getty Images
Sarah Jessica Parker and her son, James Wilkie Broderick.

Parker issued a statement on her Instagram account severing her relationship with Mylan, expressing her disappointment in the company’s actions and price hike.

“I do not condone this decision and I have ended my relationship with Mylan as a direct result of it. I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device,” she wrote.

Read the statement in full below:

A photo posted by SJP (@sarahjessicaparker) on

We reached out to Sarah Jessica Parker’s representatives about the statement, but the actress had no additional comment. Parker hasn’t been the only public figure to express dismay at Mylan’s actions. On Thursday, Hillary Clinton condemned the price increase

Mylan’s CEO Heather Bresch told CNBC on Thursday that she wants to make sure that “everybody that needs an EpiPen has an EpiPen.” The drugmaker also announced that it would offer patients a savings card to cover part of the cost. 

“As a mother I can assure you that the last thing we could ever want is no one to have their EpiPen due to price.”

Bresch has been particularly criticized over the price hike because her salary increased along with the drug’s price. Her compensation rose more than 600 percent between 2009 and 2016. 

HuffPost

BEFORE YOU GO

PHOTO GALLERY
27 Reasons Why The U.S. Shouldn't Lead The War On Drugs
CONVERSATIONS